| Formatted contents note |
TABLE OF CONTENTS<br/>Author biography, xi<br/><br/>Preface – Direction to “Perfect 24-hour Blood Pressure Control”, xv<br/><br/>Acknowledgments, xix<br/><br/>1 Evidence and scientific rationale for ambulatory blood pressure monitoring (ABPM), 1<br/><br/>Diurnal BP variation and the concept of “perfect 24-hour BP control”, 1<br/><br/>Nocturnal hypertension and nocturnal BP dipping status, 3<br/><br/>Nocturnal BP dipping status, 3<br/><br/>Non-dipper patterns of BP and pulse rate, 3<br/><br/>Riser pattern of BP and cardiovascular disease risk, 4<br/><br/>Riser pattern and HF, 7<br/><br/>Riser pattern and brain damage, 15<br/><br/>Nocturnal hypertension, 17<br/><br/>Associated Conditions and Mechanisms of Nocturnal Hypertension, 20<br/><br/>Mechanism of cardiovascular risk of nocturnal hypertension, 22<br/><br/>Extreme dipping, 24<br/><br/>Morning surge in BP, 27<br/><br/>Definition of MBPS, 33<br/><br/>Morning BP surge and cardiovascular disease, 34<br/><br/>Morning BP surge and organ damage, 37<br/><br/>Determinants of MBPS, 43<br/><br/>Mechanism of morning risk, 44<br/><br/>Morning BP surge and hemostatic abnormalities, 46<br/><br/>Vascular mechanism of exaggerated morning BP surge, 49<br/><br/>BP Variability and systemic hemodynamic atherothrombotic syndrome (SHATS), 52<br/><br/>The resonance hypothesis of BP surge, 53<br/><br/>Orthostatic hypertension, 54<br/><br/>Ambulatory BP variability, 57<br/><br/>Visit-to-visit variability in office BP, 58<br/><br/>Vicious cycle between BP variability and vascular disease—SHATS, 59<br/><br/>White-coat and masked hypertension, 71<br/><br/>White-coat hypertension, 73<br/><br/>Masked hypertension, 75<br/><br/>Advances in ABPM, 75<br/><br/>Development of information and communication technology-based multi-sensor (IMS)-ABPM, 75<br/><br/>New ABPM indices, 77<br/><br/>HI-JAMP registry, 82<br/><br/>2 Scientific rationale for HBPM, 85<br/><br/>Five prospective, general practitioner-based, home BP studies, 85<br/><br/>Morning hypertension, 85<br/><br/>Control status of morning home BP in the J-HOP study, 88<br/><br/>Evidence for morning hypertension control, 89<br/><br/>Home BP variability, 99<br/><br/>Morning–evening difference (ME-dif), 99<br/><br/>SD, CV, ARV, and VIM of home BP, 101<br/><br/>Maximum home SBP, 103<br/><br/>Orthostatic Home BP Change, 103<br/><br/>Seasonal variation of home BP and “thermosensitive hypertension”, 109<br/><br/>Alcohol, 113<br/><br/>Daytime hypertension (stress hypertension), 115<br/><br/>Nighttime HBPM, 115<br/><br/>Cutting-edge of HBPM, 115<br/><br/>Basic nighttime home BP monitoring (Medinote), 119<br/><br/>Clinical evidence using nocturnal HBPM: J-HOP nocturnal BP study, 119<br/><br/>Trigger nighttime BP monitoring, 127<br/><br/>IT-based trigger nighttime BP monitoring system and the SPREAD study, 133<br/><br/>CPAP adherence and nighttime BP surge, 135<br/><br/>Antihypertensive medication on nighttime BP surge, 139<br/><br/>Wrist home HBPM and WISDOM Night study, 145<br/><br/>3 Practical use of ABPM and HBPM, 147<br/><br/>Concept and positioning of ABPM and HBPM in guidelines, 147<br/><br/>Recent guidelines, 147<br/><br/>Diagnosis of masked and white-coat hypertension, 147<br/><br/>Definition of morning hypertension, 148<br/><br/>Definition of nocturnal hypertension, 150<br/><br/>When to use HBPM and ABPM, 150<br/><br/>Clinically suspected SHATS, 152<br/><br/>Cardio-ankle vascular index (CAVI), 154<br/><br/>Coupling study, 154<br/><br/>How to measure home BP, 155<br/><br/>Nighttime home BP measurement schedule, 159<br/><br/>ABPM parameters, 162<br/><br/>24-hour BP, 166<br/><br/>Daytime BP and nighttime BP, 166<br/><br/>Morning BP parameters, 166<br/><br/>Nighttime BP parameters, 166<br/><br/>MBPS parameters, 166<br/><br/>Nighttime BP surge parameters, 166<br/><br/>Nighttime BP dipping parameters, 167<br/><br/>ABPM-defined hypertension subtypes, 167<br/><br/>Home and ambulatory BP-guided management of hypertension, 167<br/><br/>STEpwise-Personalized 24-hour BP control approach (STEP24 approach), 167<br/><br/>Targeting morning hypertension (Step 1), 167<br/><br/>Targeting nocturnal hypertension (Step 2), 171<br/><br/>Pressor mechanism-based nighttime BP management strategy, 173<br/><br/>4 BP targets, when to initiate antihypertensive therapy, and nonpharmacological treatment, 177<br/><br/>Clinical implications of antihypertensive treatment, 177<br/><br/>SPRINT and automated office BP, 177<br/><br/>Meta-analysis of antihypertensive trials, 177<br/><br/>When to initiate antihypertensive therapy, 178<br/><br/>Patient preference, 178<br/><br/>Sodium intake, 179<br/><br/>Other dietary requirements, 181<br/><br/>Exercise, 183<br/><br/>Sleep hygiene, 185<br/><br/>Housing condition, 185<br/><br/>Applications and algorithms to facilitate lifestyle modification: CureAPP, 187<br/><br/>5 Antihypertensive medication, 189<br/><br/>Concept of 24-hour BP lowering including nighttime and morning BPs, 189<br/><br/>Chronotherapy, 189<br/><br/>Antihypertensive drug choice, 190<br/><br/>Calcium channel blockers, 190<br/><br/>Amlodipine, 194<br/><br/>Nifedipine, 195<br/><br/>Cilnidipine, 197<br/><br/>Azelnidipine, 199<br/><br/>Angiotensin-converting enzyme inhibitors, 201<br/><br/>Angiotensin receptor blockers (ARBs), 201<br/><br/>Valsartan, 201<br/><br/>Telmisartan, 204<br/><br/>Candesartan, 204<br/><br/>Olmesartan, 205<br/><br/>Azilsartan, 206<br/><br/>Diuretics, 212<br/><br/>Alpha-adrenergic blockers and beta-adrenergic blockers, 214<br/><br/>Mineralocorticoid receptor blockers (MRB), 215<br/><br/>Angiotensin receptor-neprilysin inhibitor (ARNi), 217<br/><br/>Endothelin receptor antagonists (ERA), 221<br/><br/>Combination therapy, including single pill combinations, 222<br/><br/>First-line therapy, 222<br/><br/>Second-line therapy, 222<br/><br/>Clinical trials of antihypertensive combination therapy, 226<br/><br/>Management of resistant hypertension, 238<br/><br/>Third-line therapy, 238<br/><br/>Fourth-line therapy, 239<br/><br/>SGLT2 inhibitors, 240<br/><br/>SACRA study, 243<br/><br/>SHIFT-J study, 244<br/><br/>LUSCAR study, 248<br/><br/>Summary, 250<br/><br/>Other BP-lowering therapies, 252<br/><br/>Hypnotics, 252<br/><br/>XOR inhibitor, 252<br/><br/>Herbal medication, 253<br/><br/>6 Renal denervation, 255<br/><br/>Unsolved issues in the treatment of hypertension and the era for renal denervation, 255<br/><br/>Hypothesis of perfect 24-hour BP control by renal denervation, 256<br/><br/>History, 257<br/><br/>Advances in devices, 262<br/><br/>Symplicity spyral system (radiofrequency thermal ablation), 262<br/><br/>Iberis® system, 264<br/><br/>Paradise system (ultrasonic thermal ablation), 264<br/><br/>Peregrine system (trans-arterial alcohol injection), 265<br/><br/>Other energy modalities, 266<br/><br/>Evidence for renal denervation treatment of hypertension from Sham-controlled trials, 266<br/><br/>SPYRAL trials, 266<br/><br/>Radiance-Htn Solo study, 268<br/><br/>Evidence from Japanese populations, 269<br/><br/>The Global Symplicity Registry (GSR), 269<br/><br/>Safety of the renal denervation procedure, 270<br/><br/>24-hour BP lowering profile for cardiovascular protection, 270<br/><br/>Responders and clinical indications, 272<br/><br/>7 Blood pressure linked telemedicine and telecare, 278<br/><br/>Anticipation medicine, 278<br/><br/>Innovation technology, 280<br/><br/>Concept of “trigger” management, 282<br/><br/>Multisensors and the real-time hybrid Wi-SUN/Wi-Fi transmission system, 283<br/><br/>AI and anticipation models, 284<br/><br/>Development of wearable beat-by-beat (surge) BP monitoring, 285<br/><br/>Surge index, 292<br/><br/>Disaster cardiovascular prevention (DCAP) network, 294<br/><br/>Successful anticipation model of ICT-based BP control, 302<br/><br/>Disaster hypertension, 302<br/><br/>COVID-19 era, 305<br/><br/>8 Asia perspectives, 311<br/><br/>What is the HOPE Asia Network?, 311<br/><br/>HOPE Asia Network achievements, 312<br/><br/>Characteristics of cardiovascular disease in Asia, 315<br/><br/>Obesity and salt intake in Asia, 315<br/><br/>24-hour ambulatory BP profile in Asia, 320<br/><br/>Asia BP@Home Study, 325<br/><br/>References, 328<br/><br/>Index, 368<br/><br/> |